Patents by Inventor Revati Shreeniwas
Revati Shreeniwas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12364701Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: GrantFiled: January 22, 2024Date of Patent: July 22, 2025Assignee: Respira Therapeutics, Inc.Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
-
Publication number: 20250195531Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: ApplicationFiled: February 26, 2025Publication date: June 19, 2025Applicant: Respira Therapeutics, Inc.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Patent number: 12263174Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: GrantFiled: June 29, 2022Date of Patent: April 1, 2025Assignee: Respira Therapeutics, Inc.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Publication number: 20240156827Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: ApplicationFiled: January 22, 2024Publication date: May 16, 2024Applicant: Respira Therapeutics, Inc.Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
-
Patent number: 11911390Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: GrantFiled: March 24, 2021Date of Patent: February 27, 2024Assignee: Respira Therapeutics, Inc.Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
-
Patent number: 11806314Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: GrantFiled: January 20, 2022Date of Patent: November 7, 2023Assignee: Respira Therapeutics, Inc.Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
-
Patent number: 11491161Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: GrantFiled: November 23, 2021Date of Patent: November 8, 2022Assignee: Respira Therapeutics, Inc.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Patent number: 11491160Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: GrantFiled: January 11, 2021Date of Patent: November 8, 2022Assignee: Respira Therapeutics, Inc.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Publication number: 20220347183Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: ApplicationFiled: June 29, 2022Publication date: November 3, 2022Applicant: Respira Therapeutics, Inc.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Publication number: 20220143034Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: ApplicationFiled: January 20, 2022Publication date: May 12, 2022Applicant: Respira Therapeutics, Inc.Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
-
Publication number: 20220079949Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: ApplicationFiled: November 23, 2021Publication date: March 17, 2022Applicant: Respira Therapeutics, Inc.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Publication number: 20220016126Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: ApplicationFiled: March 24, 2021Publication date: January 20, 2022Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
-
Patent number: 10912778Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.Type: GrantFiled: December 14, 2017Date of Patent: February 9, 2021Assignee: RESPIRA THERAPEUTICS, INC.Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
-
Publication number: 20160317542Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.Type: ApplicationFiled: December 9, 2014Publication date: November 3, 2016Applicant: Respira Therapeutics, Inc.Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis
-
Publication number: 20140057918Abstract: Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.Type: ApplicationFiled: August 22, 2013Publication date: February 27, 2014Applicant: XenoPort, Inc.Inventors: David J. Wustrow, Peter A. Virsik, Mark A. Gallop, Kenneth C. Cundy, Dmitri V. Lissin, Revati Shreeniwas
